NImmune Biopharma

NImmune Biopharma is a late-stage clinical precision immunology biopharmaceutical company focused on developing first-class biomarker-driven immunomodulatory therapies. Our lead clinical candidate, Omilancor, is a once-daily, gut-restricted oral therapy in Phase 3 clinical trials for the treatment of ulcerative colitis (UC), with potential applications in Crohn's disease (CD) and psoriasis.